GSK withdraws bid to use Avodart to prevent prostate cancer
Get the latest news alerts: Follow LTW at Twitter.
Associated Press
TRENTON, N.J - British drugmaker GlaxoSmithKline PLC (NYSE: GSK) said Monday it is temporarily withdrawing its application for U.S. approval of a drug to prevent prostate cancer.
The drug is already sold under the name Avodart, for treating symptoms of an enlarged prostate.
The company, which maintains its U.S. headquarters in Research Triangle Park, N.C., was seeking approval for a new use, reducing risk of prostate cancer, after research showed Avodart could reduce that risk by about 25 percent.
GlaxoSmithKline said it wants to provide an update to its application to the Food and Drug Administration. Those applications generally include thousands of pages of data on testing results and characteristics of an experimental drug.
The company said that its decision is not due to any new findings related to safety or effectiveness of Avodart.
GlaxoSmithKline, the world's No. 2 drugmaker, said it expects to resubmit its application to the FDA shortly.
The company said it will submit the same update to regulatory agencies in the European Union, after which their review of the proposed new use will begin.
In April, doctors reported that a large international study had found Avodart, known chemically as dutasteride, reduced chances of men being diagnosed with prostate cancer by 23 percent after four years' use.
Whether many men will start taking the drug preventively is unclear, given that it costs nearly $4 per daily pill and insurers may be hesitant to cover that cost.
However, last February health experts recommended that men who are regularly getting screened for prostate cancer consider taking Avodart or a competing drug, Merck & Co.'s Proscar, which also is available in a generic version called finasteride.
Every year, tens of thousands of men get results from prostate cancer screening indicating a possible problem, but then biopsies come back negative, leaving them worried and unsure what to do.
Featured
Hot Off The Wire
- Hot Off the Wire – Man convicted in first economic espionage case; iPhone market share grows; Electronic Arts shares falter after revenue forecast; Phone company wants to charge Google
- FairPoint looks to cut debt by two thirds with bankruptcy plan
- Wake Tech lands $555,680 grant for STEM education program
E-mail Preferences
The Skinny
- Gears of War 3 coming? EA discloses Epic game for 2011
- Nagoya University bridges East, West with Nu Tech event
- E-mail services provider iContact investigating a hack attack
- Cyberespionage? Cyberslueths disclose Lenovo’s 2010 ‘roadmap’
- Tech recovery is at hand, analysts tells N.C. IT execs
- Believe it - Triangle region lands record $1.9B in business projects
- Epic Games’ heroes take their guns to a new world – ‘Lost Planet 2’
- IPO rewards: Motricity CEO gets a $75,000 raise in new contract
- IT recession over? Spending will rebound, analysis firm says
- Google vs. the Dragon – War over words could ignite into flames